References
- Feldman SR, Fleischer AB, Chen GJ. Is prior authorization of topical tretinoin for acne cost-effective. Am. j Managed Cate 5, 457–463 (1999).
- Liu X, Sturm R, Cuffel, BJ. The impact of prior authorization on outpatient utilization in managed behavioral health plans. Med. Care Res. Rev 52(2), 182–195 (2000).
- •Provides analysis of walk away rates.
- MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. I Managed Care Pharm. 7(4), 297–302 (2001).
- Phillips CR, Larson LN. Evaluating the operational performance and financial effects of a drug prior authorization program. I Managed Cale P170777. 3(6), 699–706 (1997).
- Schneeweiss S, Maclure M, Walker AM et al On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Pol. 55, 97–109 (2001).
- TitiOW K, Randel L, Clancy CM, Emanuel EJ. Drug coverage decisions: the role of dollars and values. Health Aff 19(2), 240–247 (2000).
- ••Describes the place of prior authorization cost-effectiveness within the larger context of drug coverage decisions made by insurers.
- White AC, Atmar RL, Wilson J et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities and clinical outcomes. Clin. Infect. Dis. 25, 230–239 (1997).
- Wyeth-Ayerst Prescription Drug Benefit Cost and Plan Design Survey Report. Wyeth-Ayerst Laboratories, PA, USA, 11 (1999).